CDTX RSI Chart
Last 7 days
-7.8%
Last 30 days
-22.4%
Last 90 days
-21.6%
Trailing 12 Months
-55.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 46.3M | 0 | 0 | 0 |
2023 | 83.3M | 84.6M | 56.5M | 63.9M |
2022 | 54.4M | 27.8M | 61.5M | 64.4M |
2021 | 11.9M | 41.4M | 46.1M | 49.6M |
2020 | 23.9M | 26.8M | 10.2M | 12.1M |
2019 | 0 | 0 | 0 | 20.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 15, 2024 | tari leslie | acquired | - | - | 111,250 | chief scientific officer |
Mar 15, 2024 | sandison taylor | acquired | - | - | 128,750 | chief medical officer |
Mar 15, 2024 | ward shane | acquired | - | - | 120,000 | coo & clo |
Mar 15, 2024 | shah preetam | acquired | - | - | 108,750 | cfo & cbo |
Mar 11, 2024 | shah preetam | sold | -12,680 | 0.6698 | -18,931 | cfo & cbo |
Mar 11, 2024 | tari leslie | sold | -14,085 | 0.6698 | -21,029 | chief scientific officer |
Mar 11, 2024 | stein jeffrey | sold (taxes) | -39,117 | 0.69 | -56,692 | president & ceo |
Mar 11, 2024 | sandison taylor | sold | -13,839 | 0.6698 | -20,662 | chief medical officer |
Mar 11, 2024 | ward shane | sold | -13,712 | 0.6698 | -20,473 | coo & clo |
Sep 11, 2023 | tari leslie | sold | -17,508 | 0.948 | -18,469 | chief scientific officer |
Which funds bought or sold CDTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 232 | 31,156 | 42,077 | -% |
May 16, 2024 | ALETHEA CAPITAL MANAGEMENT, LLC | reduced | -1.79 | 178,243 | 1,470,610 | 1.20% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 61,865 | 61,865 | -% |
May 15, 2024 | BVF INC/IL | unchanged | - | 864,502 | 6,312,240 | 0.17% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 77,773 | 77,773 | -% |
May 15, 2024 | Point72 Asset Management, L.P. | unchanged | - | 157,500 | 1,150,000 | -% |
May 15, 2024 | STATE STREET CORP | reduced | -5.4 | 21,907 | 249,814 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -24.27 | -2,005 | 14,350 | -% |
May 15, 2024 | 5AM Venture Management, LLC | unchanged | - | 142,948 | 1,043,750 | 0.23% |
Unveiling Cidara Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cidara Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Cidara Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
Revenue | -51.9% | 8,463,000 | 17,583,000 | 12,718,000 | 7,497,000 | 26,107,000 | 10,219,000 | 40,744,000 | 6,216,000 | 7,269,000 | 7,225,000 | 7,076,000 | 32,863,000 | 2,408,000 | 3,729,000 | 2,416,000 | 3,392,000 | 2,530,000 | 1,815,000 | 19,100,000 |
Operating Expenses | -9.9% | 19,154,000 | 21,259,000 | 22,208,000 | 21,595,000 | 23,326,000 | 23,706,000 | 26,553,000 | 21,969,000 | 25,723,000 | 23,995,000 | 25,112,000 | 22,090,000 | 20,630,000 | 25,277,000 | 19,945,000 | 21,603,000 | 17,091,000 | 15,895,000 | 16,072,000 |
S&GA Expenses | 11.0% | 5,998,000 | 5,405,000 | 4,432,000 | 4,039,000 | 4,457,000 | 3,595,000 | 6,270,000 | 5,339,000 | 5,342,000 | 4,982,000 | 4,607,000 | 4,370,000 | 4,781,000 | 4,148,000 | 3,687,000 | 3,969,000 | 4,095,000 | 4,405,000 | 4,573,000 |
R&D Expenses | -21.2% | 11,593,000 | 14,718,000 | 17,389,000 | 17,556,000 | 18,869,000 | 20,111,000 | 20,283,000 | 16,630,000 | 20,381,000 | 19,013,000 | 20,505,000 | 17,720,000 | 15,849,000 | 21,129,000 | 16,258,000 | 17,634,000 | 12,996,000 | 11,490,000 | 11,499,000 |
EBITDA Margin | -38.1% | -0.84 | -0.61 | -0.38 | -0.33 | -0.40 | -0.51 | -0.69 | -1.52 | -0.77 | -0.85 | -1.55 | -1.73 | -5.98 | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | 2,000 | 13,000 | 25,000 | 38,000 | 51,000 | 64,000 | 75,000 | 88,000 | 102,000 | 116,000 | 139,000 | 144,000 | 157,000 |
Income Taxes | -100.0% | - | 64,000 | 230,000 | 149,000 | - | 272,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 100.0% | - | -3,149,000 | -8,877,000 | -13,475,000 | - | -13,325,000 | 14,246,000 | -15,759,000 | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -38.1% | -0.84 | -0.61 | -0.38 | -0.33 | -0.40 | -0.52 | -0.69 | -1.53 | -0.78 | -0.86 | -1.57 | -1.74 | -6.04 | - | - | - | - | - | - |
Net Income | -221.4% | -10,326,000 | -3,213,000 | -9,107,000 | -13,624,000 | 3,013,000 | -13,597,000 | 14,246,000 | -15,759,000 | -18,474,000 | -16,803,000 | -18,083,000 | 10,711,000 | -18,292,000 | -21,634,000 | -17,632,000 | -18,306,000 | -14,539,000 | -14,023,000 | 3,039,000 |
Net Income Margin | -118.5% | -0.78 | -0.36 | -0.59 | -0.12 | -0.15 | -0.52 | -0.60 | -2.49 | -0.78 | -0.86 | -1.03 | -1.13 | -6.35 | - | - | - | - | - | - |
Free Cashflow | 48.3% | -6,667,000 | -12,900,000 | -1,760,000 | 2,715,000 | -10,992,000 | -21,011,000 | 27,964,000 | -11,852,000 | -23,692,000 | -14,907,000 | -11,984,000 | 3,423,000 | -1,805,000 | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -21.4% | 53.00 | 67.00 | 64.00 | 68.00 | 82.00 | 47.00 | 67.00 | 39.00 | 55.00 | 75.00 | 51.00 | 64.00 | 54.00 | 60.00 | 64.00 | 73.00 | 84.00 | 69.00 | 82.00 | 52.00 | 64.00 |
Current Assets | -23.0% | 47.00 | 61.00 | 58.00 | 63.00 | 80.00 | 45.00 | 64.00 | 37.00 | 52.00 | 72.00 | 47.00 | 61.00 | 51.00 | 57.00 | 60.00 | 70.00 | 81.00 | 66.00 | 77.00 | 48.00 | 60.00 |
Cash Equivalents | -18.9% | 29.00 | 36.00 | 49.00 | 50.00 | 48.00 | 33.00 | 53.00 | 25.00 | 36.00 | 62.00 | 40.00 | 53.00 | 49.00 | 43.00 | 54.00 | 64.00 | 74.00 | 60.00 | 74.00 | 45.00 | 57.00 |
Inventory | 19.2% | 7.00 | 6.00 | 3.00 | 2.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -4.1% | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 |
Liabilities | -6.3% | 70.00 | 75.00 | 70.00 | 66.00 | 67.00 | 62.00 | 69.00 | 58.00 | 59.00 | 54.00 | 52.00 | 48.00 | 52.00 | 50.00 | 34.00 | 32.00 | 30.00 | 31.00 | 33.00 | 20.00 | 20.00 |
Current Liabilities | -3.0% | 65.00 | 67.00 | 50.00 | 45.00 | 47.00 | 41.00 | 44.00 | 42.00 | 41.00 | 34.00 | 33.00 | 34.00 | 40.00 | 39.00 | 34.00 | 32.00 | 30.00 | 30.00 | 32.00 | 19.00 | 19.00 |
Shareholder's Equity | -116.6% | -17.78 | -8.21 | 8.00 | 2.00 | 15.00 | -14.44 | 9.00 | -18.54 | 5.00 | 13.00 | - | 16.00 | 2.00 | 11.00 | 30.00 | 41.00 | 54.00 | 38.00 | 49.00 | 32.00 | 44.00 |
Retained Earnings | -2.3% | -451 | -441 | -438 | -429 | -415 | -418 | -404 | -419 | -403 | -377 | -360 | -342 | -353 | -334 | -313 | -295 | -277 | -259 | -245 | -248 | -235 |
Additional Paid-In Capital | 0.2% | 434 | 433 | 432 | 432 | 431 | 404 | 403 | 401 | 400 | 399 | 359 | 358 | 355 | 345 | 343 | 337 | 331 | 298 | 295 | 281 | 279 |
Shares Outstanding | 0.7% | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 100 | - | - | - | 33.00 | - | - | - | 98.00 | - | - | - | 151 | - | - | - | 44.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 47.8% | -6,644 | -12,722 | -1,634 | 2,822 | -10,898 | -21,002 | 27,973 | -11,836 | -23,608 | -14,907 | -11,972 | 3,440 | -1,793 | -11,128 | -14,083 | -14,072 | -15,128 | -15,197 | 16,619 | -12,808 | -17,146 |
Share Based Compensation | -4.2% | 795 | 830 | 796 | 795 | 640 | 673 | 843 | 678 | 1,338 | 1,363 | 901 | 871 | 879 | 847 | 1,002 | 995 | 1,246 | 1,023 | 1,509 | 1,257 | 1,284 |
Cashflow From Investing | 87.1% | -23.00 | -178 | -126 | -107 | -94.00 | -9.00 | -9.00 | -16.00 | -84.00 | - | -12.00 | -17.00 | -12.00 | - | -54.00 | -96.00 | -36.00 | - | - | -26.00 | -9.00 |
Cashflow From Financing | -1262.5% | -93.00 | 8.00 | - | -261 | 26,237 | 664 | 107 | -1,111 | -611 | 36,875 | -810 | 887 | 7,645 | 409 | 3,720 | 3,939 | 29,210 | 1,641 | 12,632 | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Collaboration revenue | $ 5,637 | $ 26,107 |
Product revenue | $ 2,826 | $ 0 |
Product revenue [Extensible Enumeration] | Product [Member] | Product [Member] |
Total revenues | $ 8,463 | $ 26,107 |
Operating expenses: | ||
Cost of product revenue | 1,563 | 0 |
Research and development | 11,593 | 18,869 |
Selling, general and administrative | 5,998 | 4,457 |
Total operating expenses | 19,154 | 23,326 |
Income (loss) from operations | (10,691) | 2,781 |
Other income, net: | ||
Interest income, net | 365 | 232 |
Total other income, net | 365 | 232 |
Net income (loss) and comprehensive income (loss) | (10,326) | 3,013 |
Net income (loss) and comprehensive income (loss) | (10,326) | 3,013 |
Allocation of earnings to participating securities | 0 | (636) |
Net income (loss) attributable to common stockholders | $ (10,326) | $ 2,377 |
Basic net earnings (loss) per common share (in dollars per share) | $ (2.28) | $ 0.60 |
Diluted net earnings (loss) per common share (in dollars per share) | $ (2.28) | $ 0.60 |
Shares used to compute basic net earnings (loss) per common share (in shares) | 4,537,782 | 3,932,050 |
Shares used to compute diluted net earnings (loss) per common share (in shares) | 4,537,782 | 5,059,514 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 29,018 | $ 35,778 |
Accounts receivable | 7,281 | 16,246 |
Inventory | 7,269 | 6,097 |
Prepaid expenses and other current assets | 3,266 | 2,734 |
Total current assets | 46,834 | 60,855 |
Property and equipment, net | 534 | 557 |
Finance lease right-of-use asset, net | 762 | 782 |
Operating lease right-of-use asset | 3,599 | 3,788 |
Other assets | 987 | 1,048 |
Total assets | 52,716 | 67,030 |
Current liabilities: | ||
Accounts payable | 5,055 | 3,772 |
Accrued liabilities | 8,241 | 14,177 |
Accrued indirect tax liabilities | 20,618 | 18,040 |
Accrued compensation and benefits | 5,723 | 5,034 |
Current contract liabilities | 24,324 | 25,095 |
Current portion of finance lease liability | 249 | 218 |
Current portion of operating lease liability | 1,215 | 1,082 |
Total current liabilities | 65,425 | 67,418 |
Long-term contract liabilities | 1,888 | 4,245 |
Long-term finance lease liability | 510 | 575 |
Long-term operating lease liability | 2,673 | 3,002 |
Total liabilities | 70,496 | 75,240 |
Commitments and contingencies | ||
Stockholders’ deficit: | ||
Preferred stock | ||
Common stock, $0.0001 par value; 20,000,000 shares authorized at March 31, 2024 and December 31, 2023; 4,561,696 shares issued and outstanding at March 31, 2024 and 4,530,113 shares issued and outstanding at December 31, 2023 | 1 | 1 |
Additional paid-in capital | 433,976 | 433,220 |
Accumulated deficit | (451,757) | (441,431) |
Total stockholders’ deficit | (17,780) | (8,210) |
Total liabilities and stockholders’ deficit | 52,716 | 67,030 |
Series X Convertible Preferred Stock | ||
Stockholders’ deficit: | ||
Preferred stock | $ 0 | $ 0 |